Some Sunday night biotech commentary, mainly on Jason Napadano’s reference to me on Seeking Alpha (HERE) concerning Alexza (ALXA). I also mention Star Sciences (STSI) as well.
Month: December 2012
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano, CFA which can be found at http://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/4120
Voce Capital Management Goes Hardball With Proxy Fight Against Obagi Board
Another chapter has been written on the nearly year long effort by Voce Capital management to get Obagi Medical Products (OMPI) sold, when on Monday, 12/3/12, Voce made public another letter sent to the Obagi Board of Directors (BOD) In…
XenoPort Catalyst DD – December 31st
Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
3 Small Cap Bio-Pharmas With Trade Catalysts And Speculation Investment Potential
Zogenix (ZGNX) engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the…
MEI Pharma (MEIP): Significant Catalyst Trade Potential
MEI Pharma, Inc. (MEIP), will be presenting data on Pracinostat, in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS) at a poster presentation at the American Society of Hematology Annual Meeting on December 10, 2012. An abstract of…